MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Stock List・Pulmatrix Inc

Pulmatrix Inc

Closed

2.55 2

Buy Sell

Overview

Share price change

24h

Current

Min

2.37

Max

2.55

Key metrics
By Trading Economics
Income	672K -877K
EPS	-0.24
Profit margin	-60,266.667
Employees	2
EBITDA	671K -877K

Market Stats
By TradingEconomics
Market Cap	-9.3M 8.6M
Previous open	0.55
Previous close	2.55

Pulmatrix Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Jan 2026, 23:29 UTC

Hot Stocks

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 Jan 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 Jan 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 Jan 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 Jan 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

16 Jan 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

16 Jan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 Jan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 Jan 2026, 21:48 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 Jan 2026, 21:41 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 Jan 2026, 21:38 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 Jan 2026, 20:44 UTC

Earnings

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 Jan 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 Jan 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 Jan 2026, 19:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 Jan 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 Jan 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 Jan 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 Jan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 Jan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 Jan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 Jan 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Jan 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 Jan 2026, 16:32 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 Jan 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Pulmatrix Inc Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Pulmatrix Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.